Welcome to our Investor Center. Our center is designed to provide you with convenient access to company information. For additional information on our portfolio of product candidates, please visit Pipeline.
Webcast (Replay) ACADIA Pharmaceuticals Conference Call to Discuss Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA 04/11/13 at 8:00 a.m. ET
ACADIA Pharmaceuticals Conference Call to Discuss Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA Thursday, April 11, 2013 8:00 a.m. ET
Webcast (Replay) ACADIA Pharmaceuticals Conference Call to Present Top-line Results from its Pivotal Phase III Pimavanserin Parkinson's Disease Psychosis Trial 11/27/12 at 8:00 a.m. ET
ACADIA Pharmaceuticals Conference Call to Present Top-line Results from its Pivotal Phase III Pimavanserin Parkinson's Disease Psychosis Trial Tuesday, November 27, 2012 8:00 a.m. ET
SAN DIEGO--(BUSINESS WIRE)--May. 15, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing
of an underwritten public offering of 8,000,000 shares of its common
stock, offered at a price to the public of $12.50 per share. The gross
proceeds from this offering to ACADIA are expected to be $100 million,
before deducting underwriting discounts and commissions and other
estimated offering expenses payable by ACADIA. ACADIA has granted ...
SAN DIEGO--(BUSINESS WIRE)--May. 14, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it
intends to offer and sell, subject to market and other conditions,
shares of its common stock in an underwritten public offering. There can
be no assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Jefferies LLC and Cowen and Company, LLC are acting as the joint
book-ru...
SAN DIEGO--(BUSINESS WIRE)--May. 7, 2013--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced its unaudited financial results for the first quarter ended
March 31, 2013.
ACADIA reported a net loss of $6.1 million, or $0.08 per common share,
for the first quarter of 2013 compared...
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
